A systematic review and meta-analysis of phase III trials examined whether menopausal status influences the adjuvant efficacy of CDK4/6 inhibitors in hormone receptor-positive early breast cancer. Findings suggest menopausal status may be a clinically relevant modifier of treatment benefit in this setting.
A newly published systematic review and meta-analysis in Breast Cancer Research and Treatment synthesized data from phase III randomized clinical trials evaluating adjuvant CDK4/6 inhibitors in hormone receptor-positive (HR+), HER2-negative early breast cancer, with a specific focus on whether pre- versus postmenopausal status differentially affects efficacy outcomes.
CDK4/6 inhibitors—including abemaciclib, ribociclib, and palbociclib—have demonstrated varying degrees of benefit in the adjuvant setting, but the interaction between endogenous estrogen levels and CDK4/6 inhibition remains incompletely characterized. Premenopausal women typically receive ovarian suppression alongside endocrine therapy, creating a distinct hormonal milieu that may influence cell cycle regulation and drug response compared with postmenopausal counterparts on aromatase inhibitors alone.
By pooling phase III trial data, this meta-analysis aimed to determine whether subgroup-level efficacy signals—such as invasive disease-free survival—differ meaningfully by menopausal category. Such stratification carries direct implications for treatment selection and shared decision-making in early-stage HR+ breast cancer, particularly as adjuvant CDK4/6 inhibitor use expands beyond the metastatic setting.
The full quantitative results and specific effect estimates were not available in the indexed abstract at time of publication. Clinicians should review the complete manuscript for subgroup hazard ratios, confidence intervals, and assessment of heterogeneity across included trials before applying findings to clinical practice.
Key points
- Meta-analysis pooled phase III trial data to assess whether menopausal status modifies adjuvant CDK4/6 inhibitor efficacy in HR+ early breast cancer.
- Pre- and postmenopausal women differ in hormonal environment and concomitant endocrine therapy, potentially affecting CDK4/6 inhibitor pharmacodynamics.
- CDK4/6 inhibitors evaluated in the adjuvant setting include abemaciclib, ribociclib, and palbociclib.
- Invasive disease-free survival is the primary efficacy endpoint of interest across adjuvant CDK4/6 inhibitor trials.
- Quantitative subgroup estimates were not available from the indexed abstract; full manuscript review is required for clinical application.
Why it matters
Determining whether menopausal status predicts differential benefit from adjuvant CDK4/6 inhibition could refine patient selection and inform individualized treatment decisions in HR+ early breast cancer. This is particularly relevant as oncologists weigh the benefit-risk profile of extended adjuvant therapy across diverse patient populations.